IL-27 and type 2 immunity in asthmatic patients: Association with severity, CXCL9, and signal transducer and activator of transcription signaling - 05/02/15
Abstract |
Background |
Severe asthma (SA) can involve both innate and type 2 cytokine–associated adaptive immunity. Although IL-27 has been reported to potentiate TH1 responses (including the chemokine CXCL9) and suppress TH2 responses, its function in asthmatic patients is unknown.
Objective |
We sought to evaluate IL-27 expression in human asthma alone and in combination with type 2 immunity to determine the relationship to disease severity and CXCL9 expression. We also sought to model these interactions in vitro in human bronchial epithelial cells.
Methods |
Bronchoalveolar lavage cells from 87 participants were evaluated for IL-27 mRNA and protein alone and in association with epithelial CCL26 (a marker of type 2 activation) in relation to asthma severity and CXCL9 mRNA. Human bronchial epithelial cells cultured at the air-liquid interface and stimulated with IL-27 (1-100 ng/mL) with or without IL-13 (1 ng/mL) were evaluated for CXCL9 expression by using quantitative real-time PCR and ELISA. Phosphorylated and total signal transducer and activator of transcription (STAT) 1/3 were detected by means of Western blotting. Small interfering RNA knockdown of STAT1 or STAT3 was performed.
Results |
Bronchoalveolar lavage cell IL-27 mRNA and protein levels were increased in asthmatic patients. Patients with evidence for type 2 pathway activation had higher IL-27 expression (P = .02). Combined IL-27 and CCL26 expression associated with more SA and higher CXCL9 expression (P = .004 and P = .007 respectively), whereas IL-27 alone was associated with milder disease. In vitro IL-13 augmented IL-27–induced CXCL9 expression, which appeared to be due to augmented STAT1 activation and reduced STAT3 activation.
Conclusions |
IL-27, in combination with a type 2/CCL26 signature, identifies a more SA phenotype, perhaps through combined effects of IL-27 and IL-13 on STAT signaling. Understanding these interactions could lead to new targets for asthma therapy.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, IL-27, IL-13, CXCL9, epithelial cells, signal transducer and activator of transcription 1, signal transducer and activator of transcription 3
Abbreviations used : ALI, BAL, Feno, GAPDH, HBEC, HC, ICS, IHC, qRT-PCR, SA, SARP, siRNA, STAT
Plan
| Supported by the National Institutes of Health (HL069174, HL064937, AI-40600, and RR024153) and the National Natural Science Foundation of China (No. 81470002). |
|
| Disclosure of potential conflict of interest: This study was funded by the National Institutes of Health. A. Ray is a member of the board of the American Thoracic Society, is employed by the University of Pittsburgh, and has received payment for delivering lectures from Yale University and Northwestern University. P. Ray is employed by the University of Pittsburgh and has received payment for delivering lectures from Yale University and the American Academy of Allergy, Asthma & Immunology (AAAAI). B. Freeman receives money from patents from Complexa, where he is also a shareholder. S. E. Wenzel has received funding from Amgen, ARRAY, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Sanofi Aventis, Genentech, UptoDate, ICON, and Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 135 - N° 2
P. 386 - février 2015 Retour au numéro
Article précédent
- IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers
- Michelle L. Hernandez, Katherine Mills, Martha Almond, Krista Todoric, Maria M. Aleman, Hongtao Zhang, Haibo Zhou, David B. Peden
- D prostanoid receptor 2 (chemoattractant receptor–homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells
- Sally E. Stinson, Yassine Amrani, Christopher E. Brightling
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?